Valo acquires PeptiBAC vaccine tech

By The Science Advisory Board staff writers

April 19, 2021 -- Valo Therapeutics has acquired the intellectual property rights to the University of Helsinki's PeptiBAC cancer and infectious disease vaccination technology.

PeptiBAC uses the Bacillus Calmette-Guèrin (BCG) vaccine as its base to deliver disease-specific peptides and shows prophylactic potential for diseases such as tuberculosis and treatment potential for cancer, Valo said. The BCG vaccine is widely used and tolerated, according to the firm.

PeptiBAC elicits antitumor effects and induces tumor specific CD8+ effector T cells and has been shown to increase antitumor response rates in combination with checkpoint inhibitors. Valo plans to use the technology to expand into different cancer indications with its partners.

Financial details of the deal were not disclosed.

Valo, ImmunoScape partner on pancoronavirus vaccine
Valo Therapeutics has completed a collaboration with ImmunoScape to identify immunogenic peptides for the development of a pancoronavirus vaccine.
Valo to develop pancoronavirus vaccine
Valo Therapeutics announced that it is working on the development of a potential COVID-19 vaccine with applications across future pandemics.

Copyright © 2021

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter